Evidence map›Paper›PMID 41399376›Full record

ReviewInternational journal of medical sciences2026

Polycystic Ovary Syndrome Revisited: Novel Insights and Updates.

Wenwen Zhao, Jiayi Zhou, Yanhua Song, Miao He, Xudong Zhu, Bianfang Yu, Wenxiao Gao

Abstract readReview
In one paragraph

Review in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenwen ZhaoHealth Management Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China.
Jiayi ZhouBasic Medical College, Liaoning University of Traditional Chinese Medicine, Shenyang 110847, China.
Yanhua SongHealth Management Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China.
Miao HeMedical Insurance Office, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning 110042, China.
Xudong ZhuDepartment of General Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning 110042, China.
Bianfang YuDepartment of Anorectal, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China.
Wenxiao GaoDepartment of Obstetrics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting approximately 10% of middle-aged women worldwide. The main clinical features of PCOS include hirsutism, anovulation, irregular menstruation, and polycystic ovaries. However, the exact etiology and underlying mechanisms of PCOS remain incompletely understood. Increasing evidence suggests that a variety of factors-including environmental toxins, chronic low-grade inflammation, oxidative stress, and dysregulated insulin secretion-are involved in the onset and progression of PCOS. Additionally, abnormalities in neurotransmitter metabolism play a significant role in the pathophysiology of PCOS, particularly in relation to weight gain, hyperandrogenemia, and mood disorders. Patients with PCOS often exhibit neuroendocrine system dysfunction, characterized by altered levels of neurotransmitters such as serotonin, norepinephrine, and dopamine. These changes are closely associated with clinical symptoms such as anxiety, depression, obesity, and metabolic disturbances. Current treatment strategies for PCOS primarily focus on lifestyle modifications and pharmacological interventions. These include dietary changes, nutritional supplementation, physical activity, and ovulation induction, all aimed at alleviating symptoms and improving quality of life. Notably, interventions targeting neurotransmitter metabolism are emerging as a novel area of research. The use of antidepressants, anxiolytics, and insulin-sensitizing agents has shown potential in alleviating symptoms and regulating neuroendocrine function. Furthermore, PCOS is significantly associated with metabolic dysfunction, particularly in hormone metabolism, lipid metabolism, and glucose metabolism, which exacerbates the risk of obesity, hyperandrogenemia, and type 2 diabetes. Therefore, understanding alterations in neurotransmitter metabolism and developing new therapeutic strategies may offer novel perspectives and intervention approaches for the diagnosis and treatment of PCOS.

Indexed as

Polycystic Ovary SyndromeFemaleHumansHyperandrogenismNeurotransmitter AgentsObesityOxidative StressQuality of LifeNeurotransmitter Agentsenvironmental factorsneurotransmitterspathogenesispolycystic ovary syndrometherapeutic strategies

Identifiers

PMID41399376
PMCPMC12702132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.